×

PMA

FDA

FDA raises fees 4%

By Arthur Brandwood | 09.27.2018
The new US financial year as always heralds increases in regulatory fees.  FDA published its 2019 fees at end of July. Fees are up around 4% across the board. The...
Uncertainty

Risk vs. Benefit FDA guidance gets to grips with uncertainty

By Arthur Brandwood | 09.27.2018
Doing risk management in an uncertain world is why regulatory affairs are as much art as science. Innovators will continue to push the envelope of the possible while regulators will...
Brandwood Biomedical global experts medical devices regulatory affairs consulting medical devices IVDs Brandwood Biomedical Global Expertise in Medical Device Regulatory Compliance Australia China Taiwan Hong Kong Europe New Zealand United States

Australia via 510(k): TGA – recognises US, Canadian and Japanese approvals with MDSAP

By Arthur Brandwood | 08.30.2018
Australia’s regulatory system is modelled very closely on that of Europe. This equivalence of requirements and assessment pathways has allowed TGA to leverage prior CE marking to grant Australian device...

Search

Recent Posts

TGA acceptance of international device reviews – clearing the fog

Dec 20, 2019

Brexit appears inevitable – and it seems UK MHRA will emulate New Zealand!

Dec 19, 2019

A single review program for medical devices?

Dec 2, 2019

The door to Europe is closed – so where else should I look?

Dec 2, 2019

Are Harmonised Standards facing irrelevance?

Nov 4, 2019

The question on clients’ lips… “How long will my application take?”

Nov 4, 2019

Categories

Categories

Archives

Archives

Archives

Tags

3D 3D printing 510(k) AIMD APAC Australia Biocompatibility Biomechanics Brexit CE CE Certificates clinical trials de novo distribution Europe FDA GHTF guidance Harmonization IMDRF IVD IVDD IVDR MDD MDR MDSAP medical device medical devices medicines New Zealand Notified Bodies PMA PMDA postmarket private health insurance QMS Quality Systems Reform Reimbursement SaMD Software standards Sterilisation TGA UDI
Translate »